U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

Slideshow ( 2 images )

JERUSALEM (Reuters) - Teva Pharmaceutical Industries and South Korea’s Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

The companies said the FDA has accepted the filing of CT-P6 with regulatory action expected in the first half of 2018. [nBwc10YFha]

CT-P6, already approved by the Korean Ministry of Food and Drug Safety, is a biosimilar -- a copy of a biotech drug -- to Roche Holding’s breast cancer and gastric cancer treatment Herceptin. Earlier this month, an advisory panel to the FDA recommended approval of a Herceptin biosimilar from Mylan and Biocon.

Sales of Herceptin were 3.54 billion Swiss francs ($3.65 billion) in the first half of 2017.

Celltrion and Teva last year entered into an exclusive partnership to commercialize CT-P6 as well as CT-P10 -- a biosimilar to Roche’s blockbuster biotech cancer drug Rituxan -- in the United States and Canada. The FDA is also reviewing a Biologics License Application for CT-P10, with action expected in the first half of 2018.

($1 = 0.9687 Swiss francs)

Reporting by Steven Scheer